Trading in Novo Nordisk shares by board members, executives and associated persons on 7 February 2020
Bagsværd, Denmark, 11 February 2020 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
See attached pdf for details.
|Mette Kruse Danielsen||+45 4442 firstname.lastname@example.org|
|Ken Inchausti (US)||+1 609 240 email@example.com|
|Peter Hugreffe Ankersen||+45 3075 firstname.lastname@example.org|
|Valdemar Borum Svarrer||+45 3079 email@example.com|
|Ann Søndermølle Rendbæk||+45 3075 firstname.lastname@example.org|
|Mark Joseph Root||+45 3079 email@example.com|
|Kristoffer Due Berg US)||+1 609 235 firstname.lastname@example.org|
Company announcement No 9 / 2020
Upcoming Life Sciences Events
- September 2020
- 20th Annual Biotech in Europe Forum
- US Eastern Daylight Time: BioPharm America™ 2020
- Boston CEO & BD